title: Transvaginal placement of surgical mesh for pelvic organ prolapse: more FDA concerns--positive reactions are possible.
authors.affiliation: University of New South Wales, Sydney, NSW, Australia. haylen@optusnet.com.au
authors.forename: Bernard T
authors.initials: BT
authors.lastname: Haylen
authors.forename: Peter K
authors.initials: PK
authors.lastname: Sand
authors.forename: Steven E
authors.initials: SE
authors.lastname: Swift
authors.forename: Christopher
authors.initials: C
authors.lastname: Maher
authors.forename: Paul A
authors.initials: PA
authors.lastname: Moran
authors.forename: Robert M
authors.initials: RM
authors.lastname: Freeman
mesh_terms: D005260:Female; D006801:Humans; D061214:Patient Safety; D056887:Pelvic Organ Prolapse / Q000601:surgery*; D011475:Prosthesis Failure; D019919:Prosthesis Implantation; D013526:Surgical Mesh / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
references.citation: BJOG. 2008 Oct;115(11):1350-61
references.pmid: 18715243
references.citation: Obstet Gynecol. 2010 Aug;116(2 Pt 1):293-303
references.pmid: 20664388
references.citation: Cochrane Database Syst Rev. 2010 Apr 14;(4):CD004014
references.pmid: 20393938
references.citation: Am J Obstet Gynecol. 2006 May;194(5):1438-43
references.pmid: 16579933
references.citation: Int Urogynecol J. 2011 Jan;22(1):3-15
references.pmid: 21140130
references.citation: Int Urogynecol J Pelvic Floor Dysfunct. 2007 Oct;18(10):1119-20
references.pmid: 17673944